Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

2.710 -0.150 (-5.24%)
Streaming Delayed Price Updated: 3:05 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA. 
Via Talk Markets
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
What's Going On With MindMed And Psychedelic Stocks?
Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD).... 
Via Benzinga
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring
Psychedelic medicines are rapidly gaining legitimacy on several fronts. 
Via The Motley Fool
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
Via Benzinga
Topics Cannabis
Exposures Cannabis
Compass Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript
CMPS earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
CMPS Stock Earnings: Compass Pathways Misses EPS for Q1 2024
CMPS stock results show that Compass Pathways missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'
Via Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
Who's Who In Cannabis: Latest Executive Changes You Should Know About
Via Benzinga
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD. 
Via Talk Markets
Micron, Iris Energy, Trip.com Group And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones falling around 250 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
March Recap: Largest Psychedelic Drug Stocks Up Another 5%
The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD. 
Via Talk Markets
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Via Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
Via Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
Exposures Interest Rates
The Next Great Biotech Boom Has Arrived
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
Via Benzinga
Exposures Product Safety
Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder. 
Via Talk Markets
Exposures Product Safety
MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials
Via Benzinga
Exposures Product Safety
Psychedelics 2024: Veterans Blessing, Mental Health Paradigm Shift, Providers Training, Ketamine-MDMA Bonds & More
Via Benzinga
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
All three have exciting programs on the way. 
Via The Motley Fool
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.